Ken Griffin Dyne Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,400 shares of DYN stock, worth $301,728. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,400
Previous 20,200
58.42%
Holding current value
$301,728
Previous $573,000
48.34%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$288 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$282 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$265 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$229 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$217 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.86B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...